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Abstract  The  goals  of  the  End  TB  strategy,  which  aims  to  achieve  a  90%  reduction  in  tuberculo-
sis (TB)  incidence  and  a  95%  reduction  in  TB  mortality  by  2035,  will  not  be  achieved  without  new
tools to  ﬁght  TB.  These  include  improved  point  of  care  (POC)  diagnostic  tests  that  are  meant
to be  delivered  at  the  most  decentralised  levels  of  care  where  the  patients  make  the  initial
contact with  the  health  system,  as  well  as  within  the  community.  These  tests  should  be  able  to
be performed  on  an  easily  accessible  sample  and  provide  results  in  a  timely  manner,  allowing
a quick  treatment  turnaround  time  of  a  few  minutes  or  hours  (in  a  single  clinical  encounter),s-to-follow-up.  There  have  been  exciting  developments  in  recent
ndorsement  of  Xpert  MTB/RIF,  Xpert  MTB/RIF  Ultra,  loop-mediated
B-LAMP)  and  lateral  ﬂow  lipoarabinomannan  (LAM).  However,  these
ust  be  overcome  before  they  can  be  optimally  applied  at  the  POC.LAM;
NAATs
hence avoiding  patient  los
years, including  the  WHO  e
isothermal  ampliﬁcation  (T
tests have  limitations  that  mPlease  cite  this  article  in  press  as:  García-Basteiro  AL,  et  al.  Pulmonol.  2018.
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Furthermore,  worrying  short-  to  medium-term  gaps  exist  in  the  POC  diagnostic  test  development
pipeline. Thus,  not  only  is  better  implementation  of  existing  tools  and  algorithms  needed,  but
new research  is  required  to  develop  new  POC  tests  that  allow  the  TB  community  to  truly  make
an impact  and  ﬁnd  the  ‘‘missed  TB  cases’’.
© 2017  Published  by  Elsevier  Espan˜a,  S.L.U.  on  behalf  of  Sociedade  Portuguesa  de  Pneumologia.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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uberculosis  (TB)  remains  the  leading  infectious  cause  of
eath  worldwide.  The  World  Health  Organization  (WHO)
stimated  around  10.4  million  new  cases  of  TB  in  2016  but
ess  than  two-thirds  of  these  were  diagnosed  or  reported  to
ealth  authorities.1 The  ambitious  goal  of  the  End  TB  strat-
gy  which  aims  to  achieve  90%  reduction  in  incidence  and
5%  reduction  in  mortality  by  20352 will  not  be  possible  with-
ut  new  tools  to  ﬁght  TB  (more  effective  vaccines,  shorter
reatment  regimens,  and  improved  diagnostic  tests).  Proper
nd  rapid  diagnosis  is  key  to  control  TB.
‘‘Without  diagnosis,  medicine  is  blind’’3 and  all  other
fforts  directed  to  provide  adequate  and  prompt  treatment,
nd  hence  reduce  transmission,  can  not  be  undertaken  with-
ut  diagnosis.  Improved  testing  means  not  only  developing
ighly  sensitive  and  speciﬁc  assays  to  diagnose  TB  and  drug
esistance  but  also  tests  that  are  affordable,  rapid,  and  have
he  capacity  to  be  deployed  at  the  most  decentralised  level
point  of  care,  POC)  by  health  care  workers  with  minimal
raining.  Importantly,  it  is  critical  for  programmes  to  view
he  diagnostic  process  holistically:  for  example,  POC  diag-
osis  can  be  improved  by  strengthening  infrastructure  at
rimary  care,  which  is  poor  in  most  high  burden  countries
e.g.,  through  the  provision  of  stable  electricity),  without
ecessarily  having  a  new  testing  technology.4
Nonetheless,  in  the  last  decade  we  have  witnessed
ormidable  progress  in  the  ﬁeld  of  TB  diagnostics.  Sev-
ral  assays,  such  as  Xpert  MTB/RIF  (Xpert),  Xpert  MTB/RIF
ltra  (Ultra),  urine  lateral  ﬂow  lipoarabinomannan  (LF-LAM)
r  loop-mediated  isothermal  ampliﬁcation  (TB-LAMP)  have
een  WHO  endorsed  are  being  rolled  out  progressively.5--8
hese  ‘‘approved’’  tests  are  meant  to  be  used  at  different
evels  of  care  and  with  different  advantages  and  limitations
Fig.  1).
This  review  aims  to  provide  a  snapshot  of  current  assays
hought  to  be  the  most  useful  at  POC,  Many  of  these  tests
o  not  meet  the  ideal  characteristics  of  a  POC  test  but  may
till  be  useful.  We  will  also  discuss  novel  future  assays  with
OC  potential.
oint of care vs centralised testing
lthough  improved  tests  doable  at  health  facilities  with
asic  laboratory  infrastructure  are  needed,  there  a  higherPlease  cite  this  article  in  press  as:  Ga
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rgency  for  tests  deployable  at  rural  TB  facilities  at  commu-
ity  level.  Detecting  cases  in  these  decentralised  settings,
ften  coinciding  with  areas  with  poorer  health  care  access,
s  critical.
S
m
ZMost  patients  do  not  start  treatment  the  day  of  speci-
en  provision.  There  is  a  reasonable  consensus  among  the
esearch  community  that  TB-POC  tests  must  be  deployable
t  the  most  decentralised  levels  of  care  where  the  patients
ake  the  initial  contact  with  the  health  system,  as  well  as  in
he  community  itself.  In  addition,  POC  tests  need  to  lead  to  a
apid  change  in  patient  management  (if  appropriate).9 Thus,
 POC  should  be  able  to  be  performed  in  an  easily  accessi-
le  sample  and  provide  results  in  a  timely  manner,  allowing
reatment  times  of  hours  and  hence  avoiding  patient  loss-
o-follow-up.  We  therefore  considered  only  tests  with  the
otential  to  meet  these  criteria,  either  in  rural  settings  or
ell-resourced  urban  clinics.
oint of care test target product proﬁle
he  WHO  released  a  series  of  high  priority  target  product
roﬁles  (TPPs)  for  TB  diagnosis  at  POC:  (1)  a  non-sputum-
ased  test  capable  of  detecting  all  forms  of  TB  by  identifying
haracteristic  biomarkers  or  biosignatures,  (2)  a  triage  test
hat  can  be  used  by  ﬁrst-contact  health-care  providers  to
dentify  those  who  need  further  testing,  (3)  a  sputum-based
est  to  replace  smear  microscopy  for  detecting  pulmonary
B.10
The  POC  biomarker  test  (for  non  sputum  samples)  should
nable  the  diagnosis  of  both  pulmonary  and  extra  pulmonary
uberculosis,  paediatric  TB  or  at  early  stages  of  the  disease.
t  would  need  to  be  at  least  as  sensitive  as  other  POC  tests
n  sputum  (Xpert),  portable  and.  The  triage  test  would  be
pplied  to  high  risk  patients,  most  of  whom  would  not  have
B  and  would  have  minimal  symptoms.  Thus,  the  test  needs
o  be  simple,  low  cost  and  highly  sensitive.  It  is  likely  that
his  triage  test  would  be  performed  in  the  simplest  available
ample,  such  as  breath,  blood  or  urine.  The  sputum  replace-
ent  POC  assay  needs  to  be  at  least  as  sensitive  as  Xpert,
obust  and  with  a  fast  turnaround  time  without  the  draw-
acks  of  Xpert  (i.e.,  able  to  be  used  without  power  needs  or
emperature  control).  It  is  unfeasible,  at  least  in  the  short
erm,  that  a single  test  can  include  all  these  characteristics
Table  1).
urrent point-of-care or near-point-of-care
ests
mear  microscopyrcía-Basteiro  AL,  et  al.  Pulmonol.  2018.
mear  microscopy  consists  of  examining  specimen  under  a
icroscope  to  detect  acid  fast  bacilli  after  staining  with
iehl--Neelsen  or  a  Auramine.11
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Smear microscopy
LAM
Xpert MTB/RIF
Xpert MTB/RIF
Smear microscopy
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Xpert MTB/RIF
Xpert MTB/RIF ULTRA
Solid culture (including DST)
Smear microscopy
LAM
Xpert MTB/RIF
Xpert MTB/RIF ULTRA
Portable digital X ray
ULTRA
Culture on solid&liquid media
DST (1st & 2nd line)
LPA
Other NAATs
NGS
Biomarkers
Intermediate
(regional, district, subdistrict level)
Peripheral (community level)
Referral
(reference level)
Figure  1  The  three  tiers  of  the  network  of  TB  laboratories  and  the  responsibilities  and  the  tests  offered  at  each  level.
Adapted  from  WHO.156
Table  1  TPP  of  an  ideal  POC  test  for  diagnosis  tuberculosis.10
Ideal  characteristics  of  a  POC  assay  for  diagnosing  Tuberculosis
•  It  can  detect  pulmonary  or  extrapulmonary  tuberculosis  (TB)
• It  can  be  used  in  children  and  adults,  HIV-positive  or  HIV-negative  TB  presumptive  cases
• It  can  be  used  in  several  easily  accessible  body  samples
• Used  by  health  care  workers  with  minimal  training
• Used  in  peripheral  health  facilities  or  community
• It  can  be  operated  in  broad  ranges  of  temperature  and  humidity
• Delivers  results  in  less  than  20  min
• No  or  minimal  maintenance  required
• Cheap  (less  than  4  US  dollars  per  test)
• High  sensitivity
Sensitivity  similar  to  that  of  Xpert  MTB/RIF  for  pulmonary  and  extrapulmonary  TB
If intended  to  use  as  a  triage  test  (95%  compared  to  culture)
• High  speciﬁcity
Speciﬁcity  similar  to  Xpert  MTB/RIF  for  pulmonary  and  extrapulmonary  TB
ure)
l
t
s
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r
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X
tIf intended  to  be  use  as  a  triage  test  (80%  compared  to  cult
Sputum  smear  microscopy  is  one  of  the  most  effective
tools  for  identifying  people  with  infectious  tuberculosis.
Smear-positive  patients  are  up  to  10  times  more  infectious
than  smear-negative  patients.12 The  threshold  of  detection
of  AFB  in  sputum  is  104--105 CFU/ml.  It  is  still  the  primary
method  for  diagnosis  of  TB  in  low  and  middle  income  coun-
tries  (LMIC).11,13 In  LMIC  is  the  only  cost-effective  tool  for
diagnosing  infectious  patients,  monitor  their  progress  in
treatment14 and  conﬁrm  cure.
Technically,  smear  microscopy  is  inexpensive,  easy  to
perform  and  highly  speciﬁc  in  areas  with  high  prevalence.
However,  sensitivity  values  are  low.  Maximum  sensitivity  hasPlease  cite  this  article  in  press  as:  Ga
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been  found  to  be  up  to  60%  under  optimal  conditions  when
compared  with  that  of  cultures.15
Compared  to  bright-ﬁeld  and  ﬂuorescence  microscopy,
the  Ziehl--Neelsen  technique  is  easier  to  learn.  In  contrast,
r
r
T
sight  emitting  diode  (LED)  microscopy  is  10%  more  sensitive
han  conventional  microscopy  and  98%  speciﬁc11 and  is  con-
iderably  cheaper.16 In  2011,  WHO  released  a  new  policy  on
ED  Fluorescent  Microscopy  for  TB.17
Despite  microscopy’s  advantages  of  being  cheap  and
apid,  results  are,  however,  seldom  on  the  same  day.
pert  MTB/RIF
pert  is  a  real-time  quantitative  PCR  assay  for  Mycobac-
erium  tuberculosis-complex  DNA.18 It  ampliﬁes  part  of  thercía-Basteiro  AL,  et  al.  Pulmonol.  2018.
poB  gene  that  contains  mutations  that  cause  rifampicin-
esistance  (a  critical  ﬁrst-line  drug).  Hence  Xpert  can  detect
B  and  resistance  simultaneously.  Xpert  has  shown  high  sen-
itivity  and  speciﬁcity  to  diagnose  pulmonary  tuberculosis
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Table  2  Xpert  MTB/RIF  sensitivity  and  speciﬁcity  for  pulmonary  or  extrapulmonary  tuberculosis.19,20
Pulmonary  tuberculosis  Extra  pulmonary  tuberculosis
Sensitivity  (%,  95%  CI)  (%,  95%  CI)  Sensitivity  (%,  95%  CI)  Speciﬁcity  (%,  95%  CI)
Overall  89  (84--92)  99  (98--99)  88  (77--95)  98  (87--99)
Smear-negative  68  (61--74)  99  (98--99)  69  (60--80)
Smear-positive  98  (97--99)  95  (91--100)
HIV negative  86  (76--92)  99  (98--100)
HIV positive  79  (70--86)  98  (96--99)
Smear negative  61  (40--81)
Smear  positive  97  (90--99)
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cnd  extrapulmonary  tuberculosis  (Table  2).19--21 Introduced
n  2011,  Xpert  is  WHO-approved  as  a frontline  test  for
ulmonary,  extrapulmonary,  and  paediatric  TB,6 undergone
idespread  global  scale-up  (∼25  million  cartridges  and
5,000  modules  procured  by  end  of  2016),22 revolutionised
he  diagnosis  of  TB  (75%  of  smear-negative  pulmonary  TB
ases  can  now  be  bacteriologically-detected  within  2  h),  and
aved  the  way  for  universal  drug  susceptibility  testing.19,23
Studies  have  demonstrated  Xpert  to  have  POC  feasibility
n  well-resourced  clinics  (largely  due  to  its  semi-automated
ature  that  requires  minimally  trained  non-technical
ersonnel24--27).  However,  the  test  has,  due  to  its  need
or  uninterrupted  power,  mild  ambient  conditions,  and
conomies  of  scale  (i.e.,  the  expensive  instrumentation  is
ost  cost-effective  when  used  at  volumes  that  exceeds
ates  of  specimen  collection  at  most  individual  primary
are  facilities),28 predominantly  been  implemented  in  cen-
ralised  laboratories.29
The  impact  of  the  most  widespread,  rapid  and  accu-
ate  test  for  TB  that  we  have  (Xpert)  has  thus  potentially
een  undermined  by  its  far-patient  placement.  For  exam-
le,  studies  of  POC  vs  centralised  Xpert  have  shown  POC
lacement  to  lead  to  more  cases  initiating  treatment  while
aintaining  similar  rates  of  diagnostic  accuracy.30,31 Thus,  it
ppears  Xpert’s  ability  to  provide  POC  same-day  diagnoses
educes  pre-treatment  loss-to-follow-up.
Looking  beyond  Xpert,  it  is  important  to  ask  how  can  test
evelopers  and  researchers  improve  the  impact  of  future
OC  tests?  How  can  promising  research  and  development
ctivity  be  capitalised  upon,  whilst  being  cognisant  of  the
esource  limitations  at  primary  care  in  high  burden  settings?
hat  are  the  ‘‘lessons  learnt’’  from  Xpert?
In  high  burden,  high  HIV  settings,  the  evidence  unfor-
unately  suggests  that  Xpert’s  impact  is  small,  with  no
vidence  of  long-term  improvements  in  patient  outcomes
ike  morbidity  and  mortality.24,32,33 This  is  due  to  high  rates
f  existing  empirical  TB  treatment  (most  patients  newly-
etected  by  Xpert  may  have  been  treated  on  empirical
rounds  anyway)34 and  the  still  suboptimal  sensitivity  in
pecial  populations  (HIV-positives,  children,  extrapulmonary
B).35--38 Another  important  factors  are  weak  health  sys-
ems,  which  mean  that  clinics  are  not  able  to  rapidly  startPlease  cite  this  article  in  press  as:  Ga
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pert-positive  patients  on  treatment  (this  is  especially  acute
or  rifampicin-resistant  patients39),  the  limited  affordability
f  Xpert,40 and  challenges  with  weak  testing  infrastruc-
ure  at  POC.41,42 Thus,  when  implementing  successor
t
o
Xechnologies  to  Xpert  at  POC,  health  providers  need  to  adopt
n  holistic  implementation  approach  that  includes  broad
ystems  strengthening.
Interestingly,  Xpert  has  two  additional  limitations  that
ave  dampened  enthusiasm  in  some  settings,  even  when
esults  are  generated  near  POC.  These  limit  Xpert’s  util-
ty,  as  they  increase  reliance  on  downstream  tests  like
ulture.  For  example,  patients  with  previous  TB,  who  are  an
pidemiologically-important  subpopulation  who  re-present
ith  symptoms,  have  old  mycobacterial  genomic  DNA  in
heir  lungs  that  can  cause  false-positive  results43,44 (for
ctive  TB).  Thus,  as  diagnostic  tests  improve  in  sensitiv-
ty,  speciﬁcity  is  likely  to  be  compromised  in  patients  with
 history  of  TB  unless  special  precautions  are  taken.  Fur-
hermore,  in  the  event  of  rifampicin-resistance  detection,
any  countries  still  require  conﬁrmatory  drug  susceptibility
esting,45 which  often  requires  additional  specimen  collec-
ion,  although  innovative  new  approaches  of  ‘‘hacking’’  the
sed  Xpert  cartridge  may  be  useful.46
pert  MTB/RIF  Ultra
ltra  is  a successor  technology  to  Xpert  that  uses  the  same
est  hardware.  Ultra  has  a  limit  of  detection  of  16  CFU/ml
compared  to  Xpert’s  114  CFU/ml  Xpert),  and  uses  the  same
emi-quantitative  categories  as  Xpert  (high,  medium,  low,
ery  low)  and  a  new  ‘‘trace’’  that  corresponds  to  the  low-
st  bacillary  burden.8 If  MTB  is  detected,  category  ‘‘trace’’,
hen  no  interpretation  can  be  made  regarding  rifampicin
esistance  and  results  are  reported  as  ‘MTB  detected,  trace,
IF  indeterminate.47
Overall,  sensitivity  of  the  Xpert  Ultra  is  5%  higher  than
hat  of  Xpert  (95%  CI  +2.7,  +7.8)  but  speciﬁcity  is  3.2%
ower  (−2.1,  −4.7).  A  higher  incremental  sensitivity  is  seen
mong  paucibacillary  forms  of  TB  disease  (childhood  TB,
IV-associated  TB,  or  extrapulmonary  TB  (1--3)).  However,
peciﬁcity  is  lower  in  patients  with  a  history  of  TB,  which
eans  that  among  these  patients,  Ultra  results  should  be
nterpreted  carefully,  together  with  a  comprehensive  clini-
al  history  and  physical  examination.8,48rcía-Basteiro  AL,  et  al.  Pulmonol.  2018.
Since  the  end  of  March  2017,  the  WHO  has  recommended
he  replacement  of  Xpert  by  Ultra.  The  current  WHO  rec-
mmendations  for  the  use  of  Xpert  also  apply  to  the  use  of
pert  Ultra.8
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GeneXpert  OMNI
Given  the  concerns  associated  with  the  use  of  continuous
power  and  need  for  a  lab  with  the  traditional  GeneXpert
platform,  Cepheid  has  developed  a  POC  platform.  GeneX-
pert  Omni  is  a  single  standalone  and  handheld  module  that
is  capable  of  processing  Xpert  cartridges  in  more  extreme
settings  (elevated  temperatures  and  humidity)  and  has  four
hours  of  battery  life.  It  is  intended  to  allow  GeneXpert
implementation  away  from  central  or  peripheral  settings.
Omni  is  small  and  portable,  weighing  only  1.0  kg.  It  has  a
supplemental  battery  that  gives  an  additional  12  h  Battery
life.  As  Omni  module  can  do  a  single  assay  every  ∼110  min,
cost  and  accessibility  will  limit  adoption  in  high-endemic
areas.  The  projected  release  of  the  Omni  in  emerging  mar-
kets  is  at  the  end  of  2018,  and  it  has  not  yet  been  endorsed
by  WHO22 nor  is  there  any  available  evidence  to  support  its
use.
Lateral  ﬂow  lypoarabinomannan  commercial  tests
(LF-LAM)
Lypoarabinomannan  glycolipid  is  a  component  of  the
mycobacterial  cell  wall.  In  2001  a  proof  of  concept  for
an  ELISA  detection  in  urine  was  published49 and  years
later  a  lateral  ﬂow  assay  for  LAM  detection  in  urine  was
marketed50,51 (‘Determine  TB-LAM’,  Alere, USA).  This  rapid
test  can  be  performed  at  the  bedside,  gives  a  result  in
25  minutes  and  costs  <3  USD.
In  2015,  the  WHO  released  policy  guidance7 on  LF-LAM
assays,  stating  that  the  test  may  be  used  to  ‘assist  the  diag-
nosis  of  TB  in  HIV  positive  TB  presumptive  patients  who  have
a  CD4  count  less  or  equal  to  100  cells/L, or  who  are  seri-
ously  ill  (present  with  any  one  of  four  ‘danger  signs’).  It  may
also  be  useful  in  children.52,53
LF-LAM  has  a  pooled  sensitivity  of  44%,  however,  this
varies  signiﬁcantly  according  to  health  settings  (54%  in  hos-
pitalized  patients  and  21%  in  outpatients)  and  CD4  count
(15%,  48%  and  56%  with  >200,  <200  and  <100  cells/L).
WHO  experts  discouraged  its  use  as  a  screening  tool  (among
HIV-positive  patients  regardless  of  symptoms)  because  of  a
suboptimal  speciﬁcity  of  92%.  This  low  speciﬁcity  was  con-
tentious  because  ‘false  positive’  LAM  results  could  have
been  signalling  true  TB  cases  but  sputum  negative.54 In  fact,
studies  that  sampled  more  bodily  compartments  showed  LF-
LAM  has  a  speciﬁcity  of  99%.55,56
LAM  positivity  shows  a  strong  direct  correlation  with
severity57,58 and  mortality.56--64 The  test  would  target  pre-
cisely  HIV-infected  patients  at  risk  of  longer  diagnostic
delays  (sputum  negative65--68 or  unable  to  expectorate69)  and
those  highly  immunocompromised.62,64 In  2016  a  randomised
clinical  trial  in  10  hospitals  of  4  African  countries  showed  a
17%  relative  risk  reduction  8  week  mortality  regardless  of
CD4  when  treatment  initiation  was  guided  by  the  addition
of  LF-LAM  to  standard  diagnostics.70 Thus,  LF-LAM  is  the  only
TB  diagnostic  test  with  evidence  of  a  mortality  beneﬁt.
To  better  understand  LF-LAM’s  accuracy  and  mortal-Please  cite  this  article  in  press  as:  Ga
https://doi.org/10.1016/j.rppnen.2017.12.002
ity  impact,  it  is  important  to  note  that  evidence  suggests
that  LAM  in  urine  mostly  reﬂects  the  presence  of  viable
mycobacteria  in  the  kidneys,71,72 and  blood  dissemina-
tion.  LF-LAM  positivity  correlates  very  strongly  with  results
( PRESS
5
rom  autopsies  showing  renal  or  disseminated  TB,71 posi-
ive  mycobacterial  blood  culture73 and  positivity  Xpert  in
oncentrated  urine.69
A  study  in  South  Africa  showed  that  clinicians  exerting
 very  low  threshold  for  initiating  empiric  TB  treatment
issed  cases  that  would  otherwise  have  been  diagnosed  if
AM  had  helped  their  decisions.74 WHO  classic  algorithms
or  HIV  sputum  negative  TB  suspects  and  seriously  ill  adults
eneﬁt  from  including  LAM.59,74
Nonetheless,  the  HIV/TB  research  community  continues
o  show  that  LAM  in  HIV-positive  is  useful  in  patients  beyond
hose  described  in  the  WHO  endorsement56,58,62,68,73--78 (or
ven  as  a  prognostic52,64 or  treatment  response  monitoring
ool63).  This  may  be  due  to  the  increasing  availability  of
his  true  POC  test  (rapid,  patient-side,  low  cost),  a  better
nderstanding  of  its  meaning,  and  the  efforts  driven  by  ear-
ier/rapid  antiretroviral  treatment  initiation  for  HIV,  which
an  only  be  safe  if  rapid  TB  diagnosis  is  possible.  Nonethe-
ess,  despite  being  the  only  new  TB  test  with  evidence
or  a  mortality  beneﬁt,  there  has  not  been  a  large  scale
doption  of  LAM.  Further  action  and  advocacy  is  needed  to
nclude  this  test  within  TB  diagnostic  screening  algorithms
f  severely  ill  HIV  patients.
ortable  digital  chest  X-ray  (CXR)
XR  is  unquestionably  a  very  sensitive  test.  A  recent  preva-
ence  survey  in  Kenya  showed  92%  sensitivity  for  TB  in
IV-positive  and  100%  in  HIV  negative,  but  also  low  speci-
city  (73%)  with  variations  depending  on  the  criteria  used
o  consider  ‘‘positive’’  certain  abnormalities.79 CXR  is  espe-
ially  useful  for  screening  high-risk  populations,  for  general
opulations  in  prevalence  surveys,  or  diagnosis  of  smear  neg-
tive  TB  (HIV  positive  TB  cases  or  paediatric  TB).  The  test  is
ore  sensitive  (and  no  less  speciﬁc)  than  asking  for  symp-
oms,  except  when  we  consider  ‘any  symptom’,  in  which
ase  the  sensitivity  is  similar.  When  used  in  decision  trees
r  algorithms,  CXR  should  be  placed  at  the  start  or  in  the
arly  stages,  rather  than  at  the  end  (conﬁrmatory).80 Unfor-
unately,  the  latter  is  general  practice,  but  only  because  of
perational  and  logistical  constraints  that  limit  its  availabil-
ty  to  central  facilities.
This  is  changing  today.  There  is  recognition  that  CXR  is  a
ood  tool  in  active  case  ﬁnding  strategies,  ﬁlling  the  gap  that
ymptom-based  screening  (SBS)  leaves:  it  ﬁnds  cases  that
he  latter  misses  (specially  among  HIV-positive  and  other
ulnerable  populations).  Combining  both,  and  adding  a  rapid
olecular  test  for  laboratory  conﬁrmation  of  the  disease  is
n  ideal  and  cost-effective  strategy  (CXR  serving  as  a  triage
o  reduce  the  number  of  Xpert  tests).81 The  development  of
igital  and  portable  X-ray  systems  and,  importantly,  auto-
ated  software  that  obviates  the  need  for  an  experienced
eader,  allows  to  CXR  to  be  considered  POC  test.82 A  simple
an  can  carry  an  X-ray  device  and  GeneXpert  to  any  location.
Mounting  evidence  shows  the  success  of  these  so-called
obile  units  in  three  scenarios  (Fig.  1):rcía-Basteiro  AL,  et  al.  Pulmonol.  2018.
1)  Detecting  TB  in  hard  to  reach  risk  populations  in  low  inci-
dence/high  income  countries.83,84 A  recent  systematic
review85 showed  this  is  a  highly  cost-effective  strategy.
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2)  High  incidence/medium  income  countries  such  as
India,86,87 Myanmar88 or  Philippines89 are  increasingly
using  mobile  clinics  to  bring  GeneXpert  and  Xray  to
peripheral/rural  facilities  where  TB  suspects  are  period-
ically  appointed  for  a  one-stop  (same  day)  diagnosis.87
3)  Active  case  ﬁnding  campaigns  in  aggregated  settings
(prisons,  hospices).89,90
The  digitalization  not  only  allows  portability  but  also
ele-medicine91 and  computer  aided  diagnosis  (CAD).  Their
peciﬁcity,  which  increases  by  adding  clinical  information,92
s  already  coming  close  to  human  interpretation93 (except
y  experienced  radiologists)81 making  them  a  very  attractive
ption  in  low-resourced  settings  and  remote  areas.94
ovel/future assays with potential for POC for
B diagnosis
AATs  and  next  generation  sequencing  for  TB
iagnosis (and  detection  of  drug  resistance)
espite  the  recent  advances  in  automated  PCR  technology,95
hat  are  the  next  PCR/NAAT  technological  enhancements
ecessary  for  a  same-day  point  of  care  test?  The  combination
f  decentralised  health  infrastructure  and  new  technology
mproved  ATT  initiation  from  64  to  18  days.96 There  are
umerous  other  potential  improvements  that  could  give  clin-
cians  the  ability  to  diagnose  TB  and  drug  resistance  on  the
ame  day  as  seeing  the  patient.
In  addition  to  Xpert,  there  are  other  real-time  PCR  assays
ncluding,  but  not  limited  to,  Artus  MTB  (Qiagen,  Germany),
olbio  (Bangalore,  India),  Anyplex  II  MTB/MDR  (Seegene,
orea)  and  Abbott  RealTime  MTB.  While  these  assays  are  less
utomated  than  Xpert,  the  isolated  DNA  can  be  paired  with
ther  assays,  such  as  paper-based  drug  detection  via  line
robe  assays.  The  Abbott  assay  added  additional  Mtb  gene
argets  to  improve  sensitivity.97 Most  of  these  assays  have
 relatively  small  amount  of  evidence  to  support  their  use,
equire  a  thermocycler  as  well  DNA  isolation  and  therefore
re  appropriate  in  central  and  some  peripheral  laboratory
ettings.  To  push  PCR  towards  peripheral  and  community-
ased  testing  separate  advances  are  necessary.
Potential  future  POC  diagnostic  PCR/advances  could
ome  from  (1)  isothermal  technology;  (2)  paper-based
nnovations;  (3)  quantitative  DNA  ±  RNA  assays;  and  (4)
mprovements  in  DNA  isolation  from  non-invasive,  non-
putum  specimens  such  as  urine,  stool  or  dry  blood
pot.  Loop-mediated  isothermal  ampliﬁcation  (LAMP)  has
een  used  extensively,  with  multiple  meta-analysis  describ-
ng  sensitivity  and  speciﬁcity  of  ∼89--93%  and  94--95%
espectively.98--100 In  contrast  to  RT-PCR  using  a  forward  and
everse  primer,  LAMP  uses  four  to  6  primers,  does  not  require
n  expensive  thermocycler  and  has  similar  limits  of  detec-
ion  (LOD).  As  it  does  not  need  thermocycler  or  ﬂuorescence
etection,  LAMP  technology  has  the  potential  to  decrease
est  cost  and  time  to  diagnosis  in  peripheral  labs  or  commu-
ity  settings.Please  cite  this  article  in  press  as:  Ga
https://doi.org/10.1016/j.rppnen.2017.12.002
Similarly,  a  paper-based  assay  like  the  lateral  ﬂow  assays
LFAs)  used  for  at  home  pregnancy  and  HIV  testing  shows
romise  for  improving  TB  diagnostics.  Proof  of  concept
or  nucleic  acid  LFAs  have  been  successful  detecting  Mtb
m
A
c
s PRESS
A.L.  García-Basteiro  et  al.
t  104 copies  of  genomic  DNA  as  well  as  katG  and  rpoB
enotypic  resistance.101 The  EasyNAT  (Ustar,  China)  incor-
orates  a  syringe-based  minimally  laborious  DNA  extraction
tep  with  isothermal  ampliﬁcation  (no  expensive  thermocy-
ler  required)  followed  by  a  simple  Lateral  ﬂow  detection
ethod  (LF).102 While  advances  in  portability,  simplicity  and
liminating  the  need  for  a thermocycler,  improvements  in
imit  of  detection  (LOD),  currently  >104 CFU/ml,  will  be
eeded  for  ideal  sensitivity.103
The  majority  of  PCR/s  are  designed  for  evaluating  spu-
um  specimens,  however  large  proportions  of  community
nd  peripheral  health  centres  are  not  capacitated  to  induce
putum  and  certain  populations  (PLHIV,  infants,  elderly)  are
nable  to  expectorate.  Modiﬁcations  of  existing  tests  to  use
inimally-invasive  specimen  types  such  as  urine,  stool  or
tring  test  offer  the  promise  of  increasing  diagnostic  yield,
enotypic  drug  resistance  detection  and  treatment  mon-
toring  in  patient  populations  more  likely  to  suffer  poor
utcomes.104--108
AATs  and  next  generation  sequencing  for
etection of  drug  resistance
n  combating  the  rising  number  of  cases  of  drug  resistant
B,  the  ability  of  Xpert  to  quickly  detect  rpoB  genotypic
esistance  is  improving  time  to  starting  appropriate  ther-
py.  In  order  to  prescribe  the  recently  WHO-recommended
horter  regimen,  clinicians  should  be  sure  that  RR/MDR-TB
atients  are  not  resistant  to  these  drugs,  thus  samples  need
o  be  referred  to  an  intermediate  level  laboratory  for  rapid
esting.109--116 As  the  open  and  manual  format  of  LPAs  and
he  technical  requirements  of  culture,  preclude  their  use  as
OC  tests,117 it  is  critical  that  POC  clinics  have  rapid  refer-
al  mechanisms  in  place  for  specimens  for  further  DST.  The
dvent  of  the  Xpert  XDR  cartridge  might  help  further  DST  to
e  done  more  widely.109
Next-generation  sequencing  (NGS)  is  the  next  advance
n  rapid  detection  of  genotypic  resistance  with  initial  stud-
es  suggesting  the  ability  to  identify  resistance  earlier
nd  potentially  with  improved  cost  effectiveness  compared
o  phenotypic  drug  susceptibility  testing  (DST).  Prelimi-
ary  NGS  studies  detect  genotypic  resistance  with  97--100%
oncordance  compared  phenotypic  DST.118--120 Similar  to  the
ine  probe  assays,  it  is  quite  feasible  for  NGS  to  be  performed
irectly  on  smear-positive  clinical  sputum  samples119--121
ith  INH  and  RIF  resistance  sensitivities  and  speciﬁcities  of
5--97%  and  98--100%,  respectively.  Compared  to  phenotypic
ST,  the  potential  improvements  in  times  to  drug  resistance
etection  ands  cost  provide  cautious  optimism.
To  become  a  point  of  care,  or  even  near  point  of  care
n  very  well-resourced  setting,  sequencers  will  need  to  be
ortable  (the  MinION  is  an  early  example  of  this)  and  com-
lex  bioinformatic  algorithms  will  continue  to  advance  in
fﬁcacy  and  timeliness.  When  implementing  NGS  directly
rom  sputum,  urine  or  stool,  improvements  in  bacillary
nrichment  will  decrease  background  noise  from  otherrcía-Basteiro  AL,  et  al.  Pulmonol.  2018.
icrobes  present  in  sputum  and  non-sputum  based  samples.
dditional  potential  beneﬁts  from  NGS  include  enhanced
ontract  tracing,  detection  of  subpopulations  (heterore-
istance)  and  identiﬁcation  of  pathogen  virulence  factors
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Point  of  care  diagnostics  for  tuberculosis  
(further  in-depth  reviews  of  the  hopes  and  hindrances  of
NGS  for  TB  diagnostics  are  available).122--124
Biomarkers  (host  and  pathogen)
A  biomarker  is  a  substance,  structure  or  process  that  can
predict  the  incidence  or  outcome  of  a  disease.125 To  be  used
at  POC,  biomarkers  need  to  perform  in  settings  with  lim-
ited  laboratory  facilities  and  ideally  be  low  cost  and  easy
to  use.126 In  the  last  decade,  multiple  biomarkers  with  diag-
nostic  potential  which  could  be  developed  as  POC  assays  in
the  future127 have  been  identiﬁed.  However  very  few  are
currently  available.  A  recent  review  of  399  non-DNA  poten-
tial  biomarkers  suitable  for  the  POC  concluded  that  only
12  were  validated  prospectively  and  only  one  had  reached
WHO  endorsement  for  patients  with  advanced  HIV  (lipoara-
binomannan,  LAM,  already  discussed).128 Here  we  describe
examples  of  some  of  these  other  biomarkers  with  potential
use  as  POC  tests  (Table  3):
Mtb  Ag85: The  Mtb  Ag85  complex  is  a  family  of  three
proteins  (Ag85A,  Ag85B,  and  Ag85C)  with  enzymatic  mycolyl
transferase  activity  involved  in  the  coupling  of  mycolic  acids
to  the  arabinogalactan  of  the  cell  wall  and  in  the  biogenesis
of  the  cord  factor.  Although  initially  promising,  its  detection
in  blood  and  urine  shows  highly  variable  performance129,130
and  is  not  validated  as  a  POC  assay.
Volatile  organic  compounds  (VOCs):  Exhaled  breath  may
contain  VOCs  that  could  be  derived  directly  from  Mtb  and/or
the  host  (e.g.,  products  of  oxidative  stress).  The  detection
of  VOCs  is  difﬁcult  because  they  are  excreted  in  picomolar
concentrations  and  no  devices  are  available  for  the  POC.
Several  e-nose  prototypes  (i.e.,  eNosi  Aeonose),  point-of-
care  electronic  nose  device  to  diagnose  TB  through  exhaled
breath  are  in  development,  typically  reporting  sensitivities
of  80%-88%  and  speciﬁcities  of  70--90%.131,132
Acute  phase  proteins:  recent  studies  have  revisited  the
use  of  acute  phase  proteins  such  as  C-reactive  protein  (CRP)
and  Alpha-1-acid  glycoprotein  as  triage  tests  for  TB.133 Sys-
tematic  reviews  have  described  that  CRP  has  a  sensitivity
of  90--95%  with  a  speciﬁcity  that  ranges  from  50%  to  70%
depending  on  the  setting.  A  prospective  study  in  HIV  positive
individuals  recently  reported  89%  sensitivity  results  against
culture,  and  similar  sensitivity  as  the  WHO  symptom-basedPlease  cite  this  article  in  press  as:  Ga
https://doi.org/10.1016/j.rppnen.2017.12.002
screening  when  compared  to  Xpert  MTB/RIF.133 CRP  tests  are
already  available  in  a  portable  and  designed  lock  format  and
hence  this  is  a  potential  marker  which  could  be  used  for
screening  purposes  within  active  case  ﬁnding  strategies.
i
a
a
Table  3  Host  and  pathogen  biomarkers  with  potential  for  POC  di
Biomarkers  Urine  Blood  (unstimul
From  M.
tuberculosis
LAM,  Ag85b,
DNA
DNA,  Ag  85b
From the  host  IP10  MicroRNA,  prot
and  metabolom
proﬁles,  IP10,
transcriptional  
metabolic  signa PRESS
7
A  recent  proteomic  analysis  of  1,470  samples  from
atients  described  six  host  response  markers  including
ryptophanyl-TRNA  synthetase,  kallistatin,  complement  C9,
elsolin,  testican-2,  and  aldolase  C  which  had  performed
ell  in  a  training  set  to  distinguish  TB  and  non-TB  sam-
les.  Differential  expression  was  also  high  for  many  novel
roteins  not  previously  associated  with  TB  such  as  SAA,
ecreted  phospholipase  A2  (NPS-PLA2),  and  carbonic  anhy-
rase  6  (CA6).134
A  pleural  ﬂuid  adenosine  deaminase  (ADA)  >35  U/L  has
een  reported  to  have  a  sensitivity  of  93%,  with  90%  speci-
city  for  the  diagnosis  of  TB  in  lymphocytic  exudates.  A
igh  ADA  level  is  also  detected  in  neutrophilic  TB  effusions.
owever,  extremely  high  ADA  activity  should  raise  suspi-
ion  of  empyema  or  lymphoma.135 As  ADA  levels  decrease
ith  treatment,  this  is  a  potential  biomarker  of  disease
ecovery.136,137 ADA  exceeds  Xpert’s  sensitivity  for  pleural
nd  pericardial  TB,138,139 for  which  unstimulated  interferon-
amma  is  another  promising  biomarker.
The  combined  use  of  ascitic  ﬂuid  ADA  and  serum  CA-125
n  30  patients  reported  a  sensitivity,  speciﬁcity  of  ADA  of
7%.
Several  other  human  biomarkers  have  decreased  con-
entrations  after  TB  treatment  initiation140 with  signiﬁcant
orrelations  between  CRP,  serum  amyloid  protein  A  (SAA),
ascular  endothelial  growth  factor  A  (VEGF-A),  soluble  inter-
eukin  2  receptor-alpha  (sI2R-A)/CD40,  and  -interferon
IFN)  inducible  protein  10  (IP10)  and  delayed  smear  culture
onversion.140--142 IP10  has  been  reported  to  be  high  in
nstimulated  plasma  of  children  and  adults  with  active
B.143 A  combination  of  monocyte  chemoattractant  protein-
 (MCP-1)/C-C  motif  chemokine  2  (CCL2),  IP-10,  sIL-2R,
AA,  CRP  and  smear  microscopy  smear  grade  could  dis-
inguish  fast  from  slow  responders  and  were  predictive  of
elayed  smear  culture  conversion  with  86%  and  83%  sen-
itivity  and  speciﬁcity,  respectively.  Thus,  some  of  these
iomarkers  could  play  a role  in  the  identiﬁcation  of  patients
ut  under  treatment  without  having  TB  (among  those  clini-
ally  diagnosed),  or  those  with  drug  resistant  TB  put  under
rug  susceptible  TB  combinations.144,145
The  neutrophil  driven  interferon  (IFN)-inducible  gene
roﬁle  (Type  2  [IFN) and  Type  I  (IFN) IFN  signalling]  has
 TB  signature  detectable  in  the  peripheral  blood  and  its
evels  decrease  with  effective  treatment.146
The  combined  use  of  ascitic  ﬂuid  ADA  and  serum  CA-125rcía-Basteiro  AL,  et  al.  Pulmonol.  2018.
n  30  patients  reported  a  sensitivity,  speciﬁcity  of  ADA  of  87%
nd  83%  respectively,  whereas  CA-125  had  83%  sensitivity
nd  50%  speciﬁcity.147
agnosis  of  Tuberculosis  (Modiﬁed  from  Goletti,  2016).
ated)  Blood  (stimulated)  Breath
eomic
ic
and
tures
Phenotype  by
ﬂuorescence-
activated  cell
sorting,  ELISA,
transcriptional
signatures
Volatile  organic
compounds
(VOCs)
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Although  many  of  these  markers  are  promising,  none  of
hese  biomarkers,  except  LAM  and  acute  phase  proteins,  are
vailable  in  POC  format  and  there  are  no  prototype  diagnos-
ics  at  this  stage.
ther  novel  assays
oint-of-care  diagnostic  development  should  combine  the
ost  innovative  technologies  with  effective  early  detection
nd  affordable  costs.
For  some  time,  considerable  attention  has  been  devoted
n  the  bioelectronic  ﬁeld.  Biosensors  are  analytical  devices
hat  combine  a  biological  sensing  element  with  a  physico-
hemical  transducer.  The  importance  of  biosensors  results
rom  their  high  analytical  speciﬁcity  and  sensitivity,  which
llows  the  detection  of  a  broad  spectrum  of  analysts  in  com-
lex  sample  matrices.148 Importantly,  a  biosensor  can  only
in  ideal  situations)  perform  as  well  as  the  association  of
he  biomarker  it  is  designed  to  detect  with  the  condition  of
nterest.
Also,  other  properties,  such  as  being  easy-to-operate,
conomical,  portable  and  real-time  results  provider,  iden-
ify  them  as  promising  future  diagnostic  methods.  Nucleic
cid  or  antibody  based  biosensors  have  been  built  to  detect
ifferent  molecular  targets.  There  are  several  promising
ssays  aimed  at  ﬁnding  whole  bacteria  or  deﬁning  speciﬁc
TBC  antigens:  an  amperometric  immunosensor  to  detect
TB  cells  in  sputum,  captured  on  a  microtip  surface  and
etected  by  electric  current149 or  an  immuno-sensor  devel-
pment  of  ESAT-6,  based  on  a  voltammetry  method,150 are
nly  some  of  them.
The  combination  of  nanotechnology  and  biosensing  tech-
ology  has  great  potential  in  the  medical  diagnostics  ﬁeld.148
 magnetoresistive  biosensor  to  detect  BCG  bacteria,151 a
ab-on-chip  (LOC)  platform  which  can  perform  label-free
nd  rapid  single-cell  capture152 or  a  colorimetric  sensing
trategy  employing  gold  nanoparticles153 are  very  promising
ssays.
Other  tantalizing  developments  with  potential  for  POC
ould  be  transcriptional  signatures  of  host  blood.  An
nterferon-inducible  neutrophil-driven  blood  transcriptional
ignature  distinguished  pulmonary  tuberculosis  from  other
espiratory  or  granulomatous  diseases  or  cancers.154 Other
elevant  study  showed  that  host  mRNA  signature  from
ost  blood  can  differentiate  tuberculosis  from  other  dis-
ases  in  several  cohorts  of  African  children,  regardless  of
IV  infection.155 However,  the  equipment  and  complexity
nvolved  in  the  analysis  of  transcriptional  signatures  pre-
lude  their  use  in  POC  for  now.
onclusion
lthough  we  are  emerging  from  a  period  of  unprecedented
esearch,  development,  and  implementation  for  new  TB
iagnostics,  we  have  a  limited  number  of  near  POC  tests,
nd  even  fewer  commercially-available  true  POC  tests.  None
f  these  meet  any  of  the  WHO  TPP  criteria  but  they  stillPlease  cite  this  article  in  press  as:  Ga
https://doi.org/10.1016/j.rppnen.2017.12.002
re  useful  and,  in  the  case  of  LF-LAM  for  example,  have
ompelling  evidence  to  support  their  implementation.  Fur-
hermore,  these  is  a  worrying  gap  of  late  stage  potential
OC  tests  for  TB.  Finally,  not  only  can  the  simplicity  of  tests PRESS
A.L.  García-Basteiro  et  al.
e  improved  so  they  are  deployable  at  the  POC,  but  the
onditions  at  the  POC  can  themselves  be  raised,  so  that
ore  sophisticated  tests  are  doable.  This  requires  a  holistic
pproach  to  ending  TB.
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